key: cord-0744085-s5c4b83z
authors: Li, Jie; Fink, James B; Elshafei, Ahmad A; Stewart, Laurel M; Barbian, Hannah J; Mirza, Sara H; Al-Harthi, Lena; Vines, David; Ehrmann, Stephan
title: Placing a Mask on COVID-19 Patients during High-Flow Nasal Cannula Therapy Reduces Aerosol Particle Dispersion
date: 2020-10-30
journal: ERJ Open Res
DOI: 10.1183/23120541.00519-2020
sha: af47ffdb6c11354843996d3497d5c625231b7aaa
doc_id: 744085
cord_uid: s5c4b83z

High-flow nasal cannula (HFNC) has been shown to improve oxygenation and reduce the need for intubation for hypoxemic patients [1]. A retrospective study reported the effectiveness of HFNC to improve oxygenation of COVID-19 patients [2]. The transmission route of the SARS-CoV-2 virus remains controversial [3, and concerns persist of potentially increased virus transmission when utilising HFNC among COVID-19 patients [3–5]. Computational fluid dynamic simulations reported that wearing a surgical/procedure mask over HFNC may reduce aerosol droplet dispersion [6].

High-flow nasal cannula (HFNC) has been shown to improve oxygenation and reduce the need for intubation for hypoxemic patients. 1 A retrospective study reported the effectiveness of HFNC to improve oxygenation of COVID-19 patients. 2 The transmission route of the SARS-CoV-2 virus remains controversial, 3 and concerns persist of potentially increased virus transmission when utilizing HFNC among COVID-19 patients. [3] [4] [5] Computational fluid dynamic simulations reported that wearing a surgical/procedure mask over HFNC may reduce aerosol droplet dispersion. 6 However, how far those results translate in vivo among infected patients is unknown. Furthermore, the infectious potential of dispersed aerosol droplets is uncertain. Thus, we aimed to investigate the amount of aerosol particles and their size distribution in the vicinity of COVID-19 patients during conventional nasal cannula and HFNC therapy with and without a mask, as well as virus detection in environment air samples taken during HFNC therapy. Our hypotheses were HFNC would generate similar or lower particle counts than conventional oxygen therapy and placing a mask over HFNC would reduce particle concentrations.

This prospective observational study (NCT04353531) was approved by the ethics committee (No. 20032402-IRB01, waived informed consent due to lack of contact and intervention) and implemented at Rush University Medical Center. Adult patients with laboratory confirmed COVID-19 and indicated to use HFNC were enrolled. This study was conducted in rooms of 4×4×2.8 m with a negative pressure of 0.0254 cmH 2 O and air exchange frequency of 12 times per hour.

Five minutes before HFNC started while patients were using conventional nasal cannula (1600HFTLC-7-25, Salter Labs, Lake Forest, IL), two optical particle sizers (Model 3889, Kanomax, Andover, NJ) were placed longitudinally at 1 foot (30.5cm) and 3 feet (91.5cm) away from the patient's face to measure the aerosol concentration across particle size distribution (Supplemental Figure 1) . HFNC was initiated at 50 L/min (Airvo2 and Optiflow; Fisher & Paykel Healthcare, Auckland, New Zealand) with fraction of inspired oxygen (F I O 2 ) titrated to maintain pulse oximetry saturation at 92-95%. Per institution policy, patients were encouraged to wear a surgical/procedure mask over HFNC if tolerated. Particle concentrations were continuously monitored for 5 minutes before and after the patient wearing the mask in a semi-Fowler position with the head in neutral position.

A universal pump with a 25-mm filter cassette and gelatin filters (SKC, Inc. Eighty Four, PA) was used for sampling 10 L/min of room air for 1 hour after HFNC was initiated 7 and the cassette was placed 1 foot away from the patient's face. Following aerosol sampling, 0.5 ml RNAlater® was added to the filter and cassettes were stored at 4°C. QIAamp® Viral RNA Mini kit (QIAGEN, Hilden, Germany) was used to extract RNA from gelatin filters and excess RNAlater®. Quantitative reverse transcript polymerase chain reaction (RT-qPCR) was performed on 50% of the total RNA extract using 2019-nCoV-N2 primers and probes. 8 Serial dilution of positive control plasmids containing the SARS-CoV nucleocapsid gene were used to estimate the limit of detection.

The Wilcoxon sign rank test was used to compare variables across conditions. A p-value < 0.05 was considered significant. Data analysis was conducted with SPSS software (SPSS 26.0;

Nine patients (5 male) were enrolled (mean age: 63 ± 15 years). The duration between COVID-19 confirmation and inclusion was 4 days (interquartile range: 0-7). HFNC flow was set at 50 (50-60) L/min while fraction of inspired oxygen (F I O 2 ) was set at 0.60 (0.55-0.75). Chest X-ray showed bilateral multifocal airspace opacities for all patients.

Prior to HFNC, five patients were evaluated during conventional nasal cannula at 11 (10-15) L/min, and then switched to HFNC. The remaining four patients were excluded from this analysis, due to the utilization of noninvasive ventilation (n=1), nonrebreather mask (n=1) prior to HFNC, or the lack of baseline measurement due to the immediate requirement for HFNC (n=2). For the five evaluated patients, the concentration of particles of ≤0.3µm, 0.5-1µm and 1-3µm was slightly lower with HFNC therapy compared to the conventional nasal cannula, at 3 feet away from the patients' face. Larger particles (> 5µm) were present in similar amounts (Table 1) . Among the nine patients, six patients could be evaluated with and without a mask, as three refused or could not tolerate wearing a surgical/procedure mask during HFNC therapy. The concentration of particles of 0.5-5µm at one foot from the head of the patient was lower while wearing the mask. In contrast, concentrations of smaller (≤0.3µm) and larger (5-10µm) particles were similar in both conditions. At 3 feet away, the concentration of particles was reduced while wearing a mask, but statistical significance was reached only for particles of 1-3µm ( Table 1) .

None of the room air samples showed detectable SARS-CoV-2 virus genetic material despite a detection limit of two viral copies per reaction.

Wearing a surgical/procedure mask over HFNC reduced the concentration of particles with sizes 0.5-5µm, particularly at 1 foot from the patients' face. This finding confirms results of computational fluid dynamic simulations. 6 Large particles (5-10 µm) settle at close distance and are more easily blocked by personal protection equipment. In contrast, very small particles (<0.3µm) may more readily pass through and around the mask. Our findings suggest that particles ranging from 0.5-5µm are effectively blocked or diverted by the surgical/procedure mask. 3 These results have important implications for daily clinical practice. Even though the number of very small particles far exceeds larger particles, their probability of containing viral material is much lower (virus size is estimated to be 0.125 µm, thus only very few may be contained in a < 0.5 µm droplet). Furthermore, particle of 0.5-5µm are the most likely to deposit in the respiratory tract of healthcare workers. 3 Thus, reducing their concentration in the patients' vicinity is clinically meaningful, as it may reduce the risk of healthcare workers inhaling aerosol generated by patients.

Compared to conventional nasal cannula at 10-15 L/min, the concentration of aerosol particles ≤ 5µm was lower with HFNC therapy at 3 feet from the patients' face, even though significance was not reached across the whole range of particle sizes. Our findings are consistent with reports that particle concentrations with HFNC at 50 L/min were lower than with a conventional nasal cannula at 4 L/min or a face mask at 15 L/min, with particle geometric sizes measured in the 1-2 µm range. 9 SARS-CoV-2 viral RNA was not detected in the room air samples during HFNC treatment for COVID-19 patients, consistent with prior reports that sampled negative pressure rooms 7 . This might be due to the frequent air exchange reducing the number of sampled particles, including virus-containing particles, below the limit of virus detection. 3, 7 In contrast, others detected SARS-CoV-2 in the air inside a temporary single toilet room without a ventilation system 3 and hospital rooms with no negative pressure. 10 Even though our patients were enrolled at an early phase of confirmed COVID-19 (0-7 days), the virus load carried by patients on the study day were unknown.

Aerosol transmission and deposition are complexed and affected by the room size, room air exchange frequency, the air humidity and human activity inside the room. 3 Thus our findings are limited to institutions with similar settings. Future studies are needed to investigate the mechanisms of particle movement in air with the use of different oxygen therapy devices.

Baseline particle concentrations were not measured in our study. Aerosol particles measurements were limited to 2 locations, future studies might consider several other positions in particular in the coronal plane after the patients' face. It was reported that the horizontally expelled droplets including large droplets could travel a long distance, 11 wearing the mask over HFNC might redirect the aerosol particle distribution to the coronal plane, where clinicians usually stand.

HFNC did not generate higher aerosol particle concentrations than conventional nasal cannula and wearing a surgical/procedure mask reduced aerosol particle concentrations in the patients' vicinity and should be encouraged if it is well tolerated. 

Year in review 2019: High-flow nasal cannula (HFNC) oxygen therapy for adult patients

The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing

Coughs and sneezes: Their role in transmission of respiratory viral infections, including SARS-CoV-2

High-flow nasal cannula for COVID-19 patients: low risk of bioaerosol dispersion

Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks

Preliminary findings on control of dispersion of aerosols and droplets during high-velocity nasal insufflation therapy using a simple surgical mask: Implications for the high-flow nasal cannula

Aerodynamic characteristics and RNA concentration of SARS-CoV-2 aerosol in Wuhan hospitals during COVID-19 outbreak

Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel

Aerosol generation from the respiratory tract with various modes of oxygen delivery

Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards

How far droplets can move in indoor environments--revisiting the Wells evaporation-falling curve